This segment focuses on the research, development, and clinical evaluation of novel therapeutics for chronic Hepatitis B virus (HBV) infection. Arbutus is developing several product candidates, including AB-729, a subcutaneously delivered RNA interference (RNAi) product candidate that targets hepatocytes to inhibit viral replication and reduce HBV antigens. The company also has AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. Research and development activities include preclinical studies, clinical trials, and collaborations with other pharmaceutical companies. The goal is to develop functional cures for HBV, improving patient outcomes and quality of life. This segment leverages advanced technologies like RNAi and capsid inhibition to address a significant unmet medical need. The company is strategically positioned to capitalize on the growing market for HBV treatments, with potential for significant growth through successful clinical trials and regulatory approvals.

This segment is dedicated to the discovery and development of small molecule antiviral medicines to treat coronaviruses, including COVID-19. The research and development activities include drug discovery, preclinical studies, and clinical trials. The company aims to develop effective antiviral therapies to combat current and future coronavirus outbreaks. This segment leverages expertise in virology and drug development to create innovative solutions. The focus is on addressing the global need for effective treatments against coronaviruses, with the potential for significant market impact and growth. The company is actively seeking partnerships and collaborations to accelerate the development and commercialization of its coronavirus therapeutics.